Integrative Cardiometabolic Care and Health for Obesity

Delve into integrative obesity and cardiometabolic care and discover strategies for better weight management and health improvement.

Abstract

I am Dr. Alexander (Alex) Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I present a comprehensive, clinician- and patient-facing guide to managing obesity and metabolic disease across midlife, with a special focus on adults ages 40–60. I unify the latest evidence and leading research methods in cardiometabolic risk reduction, metabolic dysfunction–associated steatotic liver disease (MASLD/MASH), sleep health (especially obstructive sleep apnea), psychiatric contributors, insulin resistance, sarcopenic obesity, musculoskeletal pain and osteoarthritis, and menopause-related transitions. I show how targeted weight reduction (often 5–15% and beyond) improves outcomes across conditions and why preserving and rebuilding lean mass is critical for metabolic health and function.
This post is grounded in our multidisciplinary model at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I integrate chiropractic medicine, functional medicine, and rehabilitation with medical oversight by Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933). Dr. Cardenas serves as our Medical Director and Collaborative Physician, providing medical direction typical of integrative and injury care clinics. Together we coordinate diagnostics, pharmacotherapy, and specialty referrals while aligning hands-on biomechanical care and graded rehabilitation to remove barriers to activity and improve long-term adherence. Throughout, I reference and hyperlink peer-reviewed, APA-7 style sources and share clinical observations from my practice and professional work (see my resources at https://chiromed.com/ and https://www.linkedin.com/in/dralexjimenez/).

Our Multidisciplinary Care Model: Medical Oversight Meets Integrative Chiropractic

I lead integrative chiropractic and functional medicine services while Dr. Maria Guadalupe Cardenas, MD, provides medical oversight and clinical governance, bringing more than 40 years of internal medicine experience. This collaboration mirrors common multidisciplinary setups in integrative and personal injury clinics, where an MD supervises medical decision-making alongside a chiropractor’s structural, neuromuscular, and rehabilitative care.
Medical leadership and safety
Dr. Cardenas ensures evidence-based standards, medication safety, and appropriate monitoring for multimorbidity and complex cases.
She co-manages diagnostics, risk stratification, pharmacotherapy choices (e.g., antihypertensives, lipid-lowering therapies, anti-obesity medications, incretin-based agents), and specialist referrals.
Integrative chiropractic and rehabilitation
I provide spine and extremity joint care, soft-tissue therapies, and neuromuscular re-education that reduce pain, optimize movement patterns, and rebuild load tolerance.
I align musculoskeletal optimization with metabolic objectives to enable and sustain aerobic and resistance training.
Functional medicine lens
Nutrition, sleep, stress, and environmental inputs are assessed alongside cardiometabolic and musculoskeletal metrics.
We use systems-oriented care to personalize nutrition and lifestyle plans and support adherence.
Team coordination and referrals
We coordinate with nutritionists, behavioral health, physical therapy, sleep technologists, cardiology, hepatology, endocrinology, gynecology, and orthopedics as needed.
This integrated approach creates a coherent, patient-centered pathway where each intervention serves a clear physiologic purpose and fits safely within the broader medical plan.

Why We Treat Obesity As A Systems Disease

Obesity is not simply excess weight; it is a systemic, chronic disease characterized by dysfunctional adipose signaling, metabolic inflexibility, mechanical overload, and neurohormonal changes. It expresses itself in multiple organs and systems:
Cardiometabolic: hypertension, atherogenic dyslipidemia, insulin resistance and diabetes, heart failure with preserved ejection fraction (HFpEF)
Hepatic: MASLD and its inflammatory and fibrotic progression to MASH
Sleep: obstructive sleep apnea (OSA) and circadian disruption
Psychiatric and psychosocial: depression, anxiety, stigma, and stress
Musculoskeletal: osteoarthritis, low back pain, deconditioning
Reproductive and endocrine: menopause transitions, sarcopenic obesity, changes in body composition
Effective care requires coordinated strategies that reduce adiposity (especially visceral and ectopic fat), preserve or build lean mass, restore sleep and circadian health, and address mood and stress. Our integrated chiropractic and functional medicine framework complements medical management to achieve these multidimensional goals.

Treatment Goals And Targets For Adults 40–60

Reduce adiposity (not just total weight)
Prioritize reductions in visceral and ectopic fat that drive cardiometabolic and hepatic risk.
Aim for 5–10% total body weight reduction (TWR) for early benefits; 10–15% or more for greater improvements in blood pressure, lipids, glycemia, HFpEF symptoms, MASLD resolution, and quality of life.
Preserve or increase lean mass
Use progressive resistance training and adequate protein to protect skeletal muscle (a key glucose sink) and maintain function and independence.
Improve cardiometabolic risk and organ health
Lower blood pressure, triglycerides, apoB-containing particles, and HbA1c; reverse or reduce hepatic steatosis; improve sleep apnea severity and daytime function.
Enhance quality of life and mobility
Reduce pain, improve gait and posture, stabilize balance, and support return to meaningful activities.
Sustain maintenance
Benefits persist when improvements in adiposity, sleep, stress, and activity are maintained. We build relapse-prevention plans and provide “booster” support through tune-ups and coaching.

The Physiology Behind Midlife Metabolic Risk

Visceral And Ectopic Fat: The Metabolic Engine Of Risk

Visceral adipose tissue is hormonally active and secretes inflammatory cytokines (e.g., TNF-α, IL-6), adipokines, and free fatty acids (FFAs).
FFAs increase hepatic gluconeogenesis and VLDL production; intramyocellular lipids impair insulin signaling.
Ectopic fat accumulates in the liver (MASLD), skeletal muscle, pancreas, and epicardial/pericardial spaces, promoting insulin resistance, endothelial dysfunction, arrhythmias, and diastolic dysfunction.
This dual burden is sometimes described as:
Sick fat disease: endocrine/inflammatory dysfunction of adipose tissue
Fat mass disease: mechanical and hemodynamic strain from elevated fat mass
Reducing total and visceral fat restores hormonal signaling, improves endothelial function, and reduces systemic inflammation.

Insulin Resistance: The Central Node

Adipose insulin resistance increases lipolysis and FFA flux, impairing hepatic and skeletal muscle insulin signaling (via DAG/PKC pathways and mitochondrial stress).
Compensatory hyperinsulinemia promotes sodium retention, sympathetic activation, and lipogenesis, perpetuating weight gain and hypertension.
Early insulin resistance can be detected with elevated fasting insulin, triglycerides, and waist circumference—even before glucose rises.
Weight loss, resistance training, and nutrition strategies that lower insulin demand can rapidly improve insulin sensitivity, sometimes preceding major weight changes.

Endothelial Dysfunction And Neurohormonal Activation

Reduced nitric oxide (NO) bioavailability and oxidative stress increase vasoconstriction and peripheral resistance.
Activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system elevates blood pressure and cardiac workload.
Physical activity, cardiorespiratory fitness, and weight loss restore endothelial function, improve arterial compliance, and reduce blood pressure.

Building A Practical Cardiometabolic Risk Profile In Clinic

With Dr. Cardenas’ medical oversight, we follow a standardized workflow to stratify risk and guide care:
Vital signs and anthropometrics
Clinic and home blood pressures (seated; orthostatic if indicated)
Waist circumference, BMI, and body composition (bioimpedance; DEXA where available)
Laboratory panels
Fasting lipids; consider apoB and Lp(a) for risk refinement
Fasting glucose and HbA1c; consider fasting insulin and HOMA-IR or composite insulin resistance indices
Liver enzymes (ALT, AST), GGT; calculate FIB-4 and NAFLD fibrosis score to screen for MASLD/MASH risk
Imaging and risk scores
Coronary artery calcium (CAC) to refine ASCVD risk in intermediate-risk patients
Echocardiography for suspected diastolic dysfunction, pulmonary hypertension, or structural heart disease
ASCVD risk calculator to guide lipid and BP therapy thresholds
Psychosocial and sleep assessment
Screen for depression (PHQ-9), anxiety (GAD-7), perceived stress, pain catastrophizing
STOP-Bang and Epworth Sleepiness Scale; refer for polysomnography when indicated
This multidimensional profile exposes modifiable drivers and aligns medical and musculoskeletal strategies with measurable outcomes.

Evidence Update: Incretin-Based Therapies And Cardiovascular Outcomes

Modern outcomes trials confirm that treating obesity itself—beyond glycemia—reduces cardiovascular risk:
Semaglutide in overweight/obesity with established CVD reduced major adverse cardiovascular events (MACE) by about 20% versus placebo, demonstrating cardioprotection in people without diabetes as a function of weight-centric therapy (Sattar et al., 2023; see also Davies et al., 2021).
In HFpEF, semaglutide improved symptoms, physical limitations, and quality of life, consistent with weight loss and anti-inflammatory effects (STEP-HFpEF findings).
Tirzepatide shows promising cardiometabolic and HFpEF-related benefits in emerging programs and has robust impacts on weight and glycemia (e.g., Jastreboff et al., 2022; SUMMIT program updates).
Under medical direction, we tailor incretin therapy based on comorbidity burden, drug interactions, and safety considerations. As weight and biomarkers improve, Dr. Cardenas supervises de-escalation of other therapies to prevent hypotension or hypoglycemia.

Four-Pillar Strategy For Stage A Heart Failure And Cardiometabolic Prevention

Nutrition
Mediterranean or DASH-style patterns emphasizing vegetables, fruits, legumes, whole grains, nuts, olive oil
Protein adequacy for muscle preservation; viscous fibers (oats, barley, legumes) for LDL lowering
Sodium and added sugar moderation; omega-3s for triglycerides and anti-inflammatory tone
Physical activity
≥150 minutes/week moderate-intensity aerobic training plus 2–3 weekly resistance sessions
Progressive loading under chiropractic-guided pain control and movement optimization
Sleep and stress
7–8 hours nightly; screen and treat OSA; optimize sleep hygiene and circadian alignment
Stress management to reduce sympathetic overdrive and support metabolic control
Risk-factor optimization and weight reduction
Evidence-based BP and lipid management; individualized glycemic targets
10–15% TWR to impact BP, diastolic function, and metabolic measures; incretin-based pharmacotherapy as indicated

Dyslipidemia In Obesity: ApoB, Triglycerides, And Diet-Activity Synergy

Pathophysiology
Insulin resistance drives hepatic VLDL overproduction and atherogenic apoB particle elevations; HDL declines; LDL shifts toward small dense particles
ApoB captures total atherogenic particle burden and often remains elevated despite moderate LDL-C (Mehta et al., 2022; Toth et al., 2020)
Assessment and therapy
Standard lipid panel plus apoB and Lp(a) when appropriate; ASCVD risk estimation to guide statin intensity
Weight reduction (5–15%), Mediterranean pattern, viscous fiber, aerobic and resistance training
Statins first-line; ezetimibe and PCSK9 inhibitors in high-risk patients; omega-3 ethyl esters or fibrates for hypertriglyceridemia
Chiropractic and rehab enable sustained exercise adherence by reducing pain, improving joint kinetics, and ensuring safe progression.

Hypertension In Obesity: Mechanisms And Management

Mechanisms
Expanded blood volume and cardiac output; RAAS and sympathetic activation; endothelial dysfunction; decreased vascular compliance
Systolic BP increases with weight gain; modest loss (3–9%) lowers systolic and diastolic BP by ~3 mm Hg; larger losses yield larger drops
Practical approach
Aim for 10–15% TWR
DASH diet with mindful sodium reduction, potassium-rich foods
150 minutes/week aerobic plus resistance training; home BP monitoring
Medication adjustments under medical supervision as weight and BP improve

MASLD/MASH: Screening, Fibrosis Risk, And Integrated Treatment

Spectrum and pathogenesis
From steatosis to steatohepatitis (MASH) with inflammation and fibrosis
Insulin resistance increases de novo lipogenesis; oxidative stress and mitochondrial dysfunction promote hepatocellular injury
Screening and risk stratification
ALT/AST may be normal; use FIB-4 and NAFLD fibrosis scores periodically
Consider elastography (FibroScan) or MRI-PDFF in higher-risk patients
Assess cardiometabolic risk comprehensively—MASLD is a hepatic manifestation of systemic metabolic dysfunction (Yki-Järvinen, 2016; hepatology practice updates)
Treatment
7–10% TWR reduces steatosis; 10–15% can resolve steatohepatitis and regress fibrosis in some
Mediterranean-leaning, lower refined-carbohydrate pattern; physical activity reduces hepatic fat independent of weight
Incretin therapies reduce hepatic fat and inflammation; resmetirom has emerged for MASH with F2–F3 fibrosis (managed with hepatology)
Chiropractic and rehab facilitate the physical capacity necessary for sustained activity, which is central to hepatic improvement.

Sleep And Obstructive Sleep Apnea: The Metabolic-Sleep Feedback Loop

Bidirectional links
Upper-airway narrowing with increased adiposity promotes OSA
Intermittent hypoxia and sleep fragmentation worsen insulin resistance, hypertension, dyslipidemia, and arrhythmias
Poor sleep dysregulates ghrelin and leptin, increasing appetite and weight gain risk
Assessment and management
STOP-Bang and Epworth screening; polysomnography for diagnosis and AHI staging
CPAP as cornerstone; adherence support is crucial
Weight loss (5–15%) reduces AHI; tirzepatide is FDA-approved in OSA with obesity, reflecting AHI reductions paralleling weight loss
Chiropractic care supports thoracic mobility, diaphragmatic mechanics, and posture—benefiting breathing, sleep comfort, and exercise tolerance

Psychiatric And Psychosocial Considerations: Depression, Anxiety, Stigma, And Adherence

Psychosocial dynamics
Elevated prevalence of depression and anxiety; stress and sleep loss amplify inflammation and cravings
Weight stigma and internalized bias hinder help-seeking and adherence
Integrated approach
Routine PHQ-9, GAD-7, and perceived stress screening
Cognitive-behavioral strategies, therapy referrals, group support or coaching
Medication reviews to avoid weight-promoting agents when alternatives exist
Respectful, nonjudgmental communication and shared decision-making increase trust and engagement
As a clinician, I often see emotional relief when pain is acknowledged and effectively treated. With pain reduced and sleep stabilized, patients’ momentum increases—they move more, eat more intentionally, and experience deeper metabolic improvements.

Menopause And Midlife Women’s Health: Metabolism, Body Composition, And VMS

Hormonal transitions
Estrogen decline shifts fat storage to the abdomen, increases visceral fat, reduces resting energy expenditure, and alters lipids
Appetite hormones change (ghrelin may rise); sleep disruption and vasomotor symptoms (VMS) impair daily function and adherence
Body composition shifts
Increased central adiposity and decreased lean mass (sarcopenia); bone density declines increase osteoporosis risk
Even modest weight gain in menopause can mask unfavorable body composition changes if lean mass is declining
VMS and weight: a vicious cycle
Higher BMI and waist circumference are associated with more frequent and severe VMS
Weight reduction decreases VMS frequency and severity by improving thermoregulation and reducing insulating fat layers
Tailored strategies
Resistance training to counter sarcopenia and support bone
Cardiometabolic risk control (lipids, blood pressure, insulin resistance)
Consider menopausal hormone therapy (MHT) when appropriate; non-hormonal options when indicated
Sleep optimization and stress care; nutrition with adequate protein to overcome anabolic resistance
Chiropractic care addresses joint mechanics, spinal health, and posture—enabling adherence to activity prescriptions crucial during the menopausal transition.

Sarcopenic Obesity: The Hidden Epidemic, Especially In Midlife Women

Definition and prevalence
Sarcopenic obesity combines low muscle mass/strength with elevated fat mass, accelerating frailty and metabolic disease (Zamboni et al., 2019)
Prevalence rises with age; disparities exist by ethnicity and comorbidity (e.g., higher rates with diabetes and MASLD)
Clinical features
Profound fatigue and weakness, heaviness with movement, limited range of motion, functional decline in activities of daily living
BMI can mislead; body composition assessment (DEXA or BIA) plus functional tests (grip strength, chair stands) are needed
Mechanisms
Visceral fat cytokines and adipokines promote muscle catabolism
Reduced physical activity and insulin resistance compound muscle loss
Weight cycling without adequate protein accelerates unfavorable body composition shifts
Treatment pillars
High-protein nutrition (often 1.2–1.8 g/kg ideal body weight/day), leucine-rich sources, and distribution of protein every 3–4 hours to stimulate muscle protein synthesis (Bauer et al., 2013)
Progressive resistance training to drive hypertrophy; aerobic activity to support cardiometabolic health
Chiropractic to restore joint mobility, improve neuromuscular control, and reduce pain; physical therapy referrals for structured strength progression
Pharmacotherapies that support weight loss without worsening muscle loss; medical oversight to taper weight-promoting agents when feasible

Integrative Chiropractic Care: Why Biomechanics Matter For Metabolic Health

Musculoskeletal optimization
Spinal and extremity joint care to restore arthrokinematics and range of motion
Soft-tissue and fascia techniques to reduce nociception, improve glide, and decrease tone
Neuromuscular re-education
Motor control training (core stability, hip hinge, scapular mechanics, gait retraining)
Balance and vestibular work to reduce fall risk and increase confidence
Pain modulation and load tolerance
Multimodal pain strategies reduce central sensitization and enable progressive loading
As pain falls and movement quality improves, adherence to aerobic and resistance training rises—and metabolic markers improve accordingly
Clinical observations from my practice (shared at https://chiromed.com/ and on my profile at https://www.linkedin.com/in/dralexjimenez/) consistently show that integrated musculoskeletal support increases exercise adherence and improves function and quality of life—key enablers of durable metabolic change.

Functional Medicine Integration: Systems Biology In Daily Practice

Root-cause assessment
Nutritional status, gut-liver axis, micronutrients (e.g., vitamin D, magnesium), and inflammation markers
Sleep and circadian alignment, stress load and HPA axis tone
Personalized nutrition and behavior design
Mediterranean/DASH cores with carbohydrate distribution tailored to insulin resistance
Protein targets that counter anabolic resistance; fiber enrichment; omega-3 sufficiency
Habit stacking, environment design, and iterative goal-setting to sustain engagement
Stress resilience
Mindfulness and breathing practices; HRV-informed training; recovery prioritization to normalize autonomic balance
Functional medicine provides the scaffolding to translate evidence into lived habits, bridging medical therapy and daily behaviors that sustain outcomes.

Personal Injury And Rehabilitation: Keeping Metabolic Progress On Track

Injury-aware protocols
Avoid aggravating hypertension, ischemia, or cardiac disease during rehab
Coordinate imaging and red-flag evaluation under medical oversight
Graded activity respecting tissue healing timelines while maintaining cardiometabolic momentum
Practical benefits
Patients remain engaged in activity and avoid prolonged deconditioning
Pain and disability are addressed within the broader health goals of weight, sleep, and metabolic control

Translating Evidence Into Practice: Why Each Lever Works

Weight reduction (5–15% and beyond)
Reduces visceral fat, improves hepatic lipid handling, lowers inflammatory signaling, restores insulin sensitivity
Improves BP, lipids, HFpEF symptoms, AHI in OSA, and quality of life
Aerobic and resistance training
Increase mitochondrial density and oxidative capacity, GLUT4 translocation, endothelial function, and autonomic balance
Preserve and build lean mass for resting metabolic rate and glucose disposal
Mediterranean/DASH nutrition
Lowers LDL and apoB, reduces blood pressure, improves glycemic control, supports microbiome diversity and anti-inflammatory tone
GLP-1/GIP-based pharmacotherapy
Improves satiety and glycemic control, slows gastric emptying, reduces energy intake, and supports MASLD improvement
Demonstrates CV risk reduction in high-risk cohorts
Sleep optimization
Restores appetite hormone balance (ghrelin/leptin), improves insulin sensitivity, and reduces sympathetic strain
Chiropractic and rehabilitation
Remove mechanical barriers to movement, reduce pain and fear-avoidance, and enhance proprioception to enable sustained training
Medical oversight
Ensures safety, accurate diagnosis, and appropriate monitoring with evidence-based therapy selection and titration
Each component amplifies the others. For example, better sleep strengthens appetite regulation; pain reduction unlocks physical capacity; pharmacotherapy makes nutritional plans easier to follow; and medical supervision aligns these steps with safety and precision.

Practical Clinic Workflow: From Intake To Maintenance

Initial assessment
Comprehensive medical history, physical exam, anthropometrics, body composition
Labs (glucose, HbA1c, lipids, liver enzymes, insulin as indicated), psychosocial and sleep screening
Musculoskeletal evaluation for pain generators and movement patterns
Collaborative plan
Specific, measurable targets (e.g., 10% TWR in 6–12 months)
Nutrition and exercise prescriptions with chiropractic and rehab support
Pharmacotherapy under Dr. Cardenas’ oversight; consider incretin therapies, metformin, SGLT2 inhibitors, statins, ACEi/ARBs
Sleep optimization and referrals; behavioral health support as needed
Follow-up cadence
Track weight, BP, labs, pain/function scores, sleep adherence, and progress
Adjust loading and intensity as capacity improves; titrate medications as biomarkers normalize
Maintenance and relapse prevention
Schedule musculoskeletal tune-ups, periodic nutrition and sleep check-ins
Plan for life transitions, travel, and stressors; reestablish routines quickly after lapses

Case Narratives: Real-World Integration

Case 1: A 52-Year-Old Male With Central Obesity, Hypertension, And Hypertriglyceridemia

Starting profile: central adiposity, elevated BP, high triglycerides, low back pain limiting walking
Plan: Mediterranean-DASH nutrition, 150 minutes/week aerobic activity, resistance training, chiropractic care to enable ambulation and reduce pain
Progress: 8% weight loss brought BP and triglycerides down; statin adjusted per ASCVD risk; semaglutide added for appetite control to target 12–15% TWR; walking increased to 30–45 minutes daily with less back pain
Physiologic rationale: Improved insulin sensitivity lowers hepatic VLDL output; resistance training preserves muscle for glucose disposal; chiropractic care restores gait mechanics and reduces nociception, enabling sustained activity.

Case 2: A 48-Year-Old Perimenopausal Woman With OSA And Anxiety

Starting profile: OSA with poor sleep, neck/shoulder tension, anxiety, and weight gain
Plan: CPAP refitting and adherence support; chiropractic care to reduce cervical/thoracic tension; resistance training to preserve lean mass; tailored nutrition to mitigate vasomotor triggers; behavioral support
Progress: 10% weight loss reduced AHI and BP; mood improved on PHQ-9; better sleep enabled consistent exercise
Physiologic rationale: CPAP and weight loss alleviate intermittent hypoxia and sympathetic drive; resistance training and protein adequacy combat anabolic resistance; chiropractic care improves thoracic mobility and breathing mechanics.

Case 3: A 60-Year-Old With MASLD And Prediabetes

Starting profile: elevated ALT/AST, hepatic steatosis, prediabetes, knee osteoarthritis
Plan: Mediterranean-leaning, lower refined-carbohydrate nutrition; GLP-1 RA; resistance training with knee-stabilizing rehab and chiropractic input
Progress: 12% TWR improved liver enzymes and hepatic fat fraction; knee stability improved adherence to training; insulin sensitivity improved
Physiologic rationale: Weight loss reduces hepatic fat and improves insulin signaling; incrementally loaded resistance work builds muscle and supports glucose control; biomechanical improvements protect joints during progression.

Integrated Metabolic Transformation: Robert’s Three-Year Journey

To bring it all together, here is a composite narrative based on patients we see, presented earlier in my segment summaries but expanded here to illustrate the integrated model.
Demographics and history
55-year-old Mexican American male, class III obesity, type 2 diabetes (HbA1c 8.5%), dyslipidemia, hypertension, OSA with poor CPAP adherence, knee osteoarthritis, low libido, elevated liver enzymes suggestive of MASLD, stress and mild depression
Medications: metformin, glipizide, lisinopril, rosuvastatin
Stepwise plan
Nutrition: lower-carbohydrate Mediterranean-style pattern; protein-focused breakfasts; evening craving strategies; hydration and electrolytes
Activity and rehab: start with pool and cycling; progress to resistance training targeting quadriceps, gluteals, and core; ergonomic coaching; chiropractic mobilization for knees and lumbopelvic region; thoracic mobility for posture and breathing
Sleep: CPAP refit and adherence coaching; sleep hygiene; nasal and reflux assessment if indicated
Pharmacotherapy (under Dr. Cardenas): continue metformin; gradually taper off glipizide; initiate tirzepatide with careful titration; manage antihypertensives and statins with monitoring; address sexual health and evaluate testosterone in context of sleep and metabolic control
Goals and milestones
Year 1: target 10% TWR; reduce HbA1c toward <7%; improve triglycerides and AHI
Year 2–3: achieve ~20–27% TWR; stabilize HbA1c near non-diabetic range; reduce medication burden as tolerated
Outcomes
Weight loss of ~27%; improved HbA1c and triglycerides; better BP control; improved CPAP adherence; lower knee pain; increased energy and confidence
Why it worked
Lower insulin demand, increased GLUT4-mediated glucose uptake via exercise, hepatic fat reduction, and enhanced insulin sensitivity
Biomechanical relief enabling sustained activity; better sleep rebalancing appetite hormones; modern incretin therapy amplifying weight and glycemic control
Continuous medical oversight ensured safe titration and timely de-escalation of weight-promoting medications

Menopausal Metabolic Maze: Maggie’s Early Intervention

Profile
53-year-old CPA; perimenopausal symptoms, gradual weight and waist increase, fasting insulin elevated; HbA1c 5.8% (prediabetes); nightly wine for stress; walks dog daily; gabapentin for VMS; dyslipidemia emerging
Plan
Nutrition: 90–100 g protein/day distributed every 3–4 hours; 50–100 g net carbs from high-fiber sources; collaborative reduction of nightly alcohol
Activity: maintain walking but add moderate-intensity sessions; begin resistance training 1x/week, progress to 2x/week
Medical: metformin ER 500 mg qPM with slow titration; reassess gabapentin effectiveness; discuss MHT suitability; consider CBT-I and sleep hygiene; consider GLP-1 RA if insufficient response after 3–6 months
Rationale
Early insulin resistance is reversible; protein plus resistance training counter anabolic resistance; reducing alcohol improves sleep and glycemia; early medical therapy supports prevention

Severe Sarcopenic Obesity With Comorbidities: Maria’s Assertive Plan

Profile
59-year-old with prior MI, 10-year T2D (on insulin), hypertension, dyslipidemia, MASLD/MASH, severe knee osteoarthritis; DEXA: body fat 57.8%, muscle mass 4th percentile, VAT 3.4 L, waist 43.5 inches
Plan
Nutrition: high-protein (1.5–1.8 g/kg ideal weight), lower refined carbohydrates; micronutrient sufficiency
Physical therapy: sarcopenia and deconditioning protocol; knee-sparing strength; aquatic training and stationary biking; chiropractic adjustments to improve joint mobility and reduce pain
Orthopedic referral: evaluation for injections or total knee replacement; clinician advocacy to counter bias
Medical: initiate semaglutide for diabetes, obesity, and MACE risk reduction; carefully taper and discontinue insulin as control improves; manage BP and lipids aggressively; hepatology coordination as needed
Rationale
Incretin therapy addresses glycemia, weight, and CV risk simultaneously; reducing exogenous insulin lowers weight-promoting pressure; PT and chiropractic restore safe movement patterns; surgical intervention may unlock mobility and long-term weight stability

Practical Tools And Monitoring In Clinic

Annual metabolic screen
Weight, waist, BMI, body composition
Fasting glucose, HbA1c, lipids, CMP, CBC, urinalysis
Fasting insulin/HOMA-IR or composite IR indices when appropriate
Liver and fibrosis monitoring
ALT, AST, FIB-4 at intervals; elastography for elevated risk
Reassess with weight loss and pharmacotherapy adjustments
Sleep and mood
STOP-Bang, Epworth, polysomnography; PHQ-9, GAD-7, stress scales
CPAP adherence checks; behavioral therapy referrals
Function and pain
Timed up-and-go, grip strength, chair stands; pain scales; gait analysis
Progressive loading plans with chiropractic and PT collaboration
Follow-up rhythm
Every 4–8 weeks initially; adapt based on progress and medication titration
Long-term maintenance with periodic booster sessions

The Role Of Care Environment: Trust, Bias Awareness, And Shared Success

Active listening and shared decision-making
Nonjudgmental language focused on function, health markers, and life quality
Realistic milestones beyond the scale: sleep improvement, pain reduction, endurance gains
Continuity through check-ins for accountability and rapid problem-solving
Trust accelerates outcomes. When patients feel seen and supported, adherence improves, setbacks shorten, and gains stabilize.

Key Takeaways For Patients And Clinicians

Identify insulin resistance early—often a decade before diabetes—and treat it proactively
Use lower-carbohydrate strategies judiciously to reduce insulin demand; ensure protein sufficiency to preserve muscle
Combine aerobic and resistance training under pain-aware, biomechanics-guided progressions
Screen and manage MASLD/MASH with weight loss, activity, and hepatology where indicated
Address sleep, stress, and mood to unlock metabolic progress
Consider incretin-based therapies and modern pharmacology to catalyze weight and risk reduction
Leverage chiropractic and PT to remove mechanical barriers, reduce pain, and sustain training
Maintain an inclusive, bias-aware clinical culture that promotes trust and adherence

Safety, Ethics, And Patient-Centered Communication

Informed consent for all interventions with clear benefit-risk dialogue
Respectful, stigma-free language; focus on health, function, and quality of life
Shared decision-making honoring preferences, resources, culture
Continuous quality improvement and alignment with up-to-date evidence

Conclusion: A Coherent, Integrated Path To Midlife Health

Obesity care for adults 40–60 delivers the best outcomes when medical oversight, metabolic science, and musculoskeletal optimization are integrated into one coherent plan. Under Dr. Maria Guadalupe Cardenas’ medical direction and through my hands-on, functional approach to chiropractic and rehabilitation, we implement interventions that are physiologically sound, evidence-based, and patient-centered.
The modern literature—from incretin cardiovascular outcomes to HFpEF symptom trials, from MASLD reversal with weight loss to OSA improvements with weight and CPAP—confirms what we see daily: targeted adiposity reduction, lean mass preservation, sleep normalization, stress resilience, and coordinated pharmacotherapy reduce cardiovascular events, improve liver and heart function, lower blood pressure and lipids, and restore quality of life. Our role is to make this achievable—remove barriers, align strategies with physiology, and coordinate care through a trusted multidisciplinary team.
For clinical observations and further insights into our methods and philosophy, explore my practice resources at https://chiromed.com/ and my professional profile at https://www.linkedin.com/in/dralexjimenez/.

References

• American College of Cardiology/American Heart Association. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Journal of the American College of Cardiology.
• American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care.
• Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., Phillips, S., Sieber, C., Stehle, P., Teta, D., Visvanathan, R., Volpi, E., & Boirie, Y. (2013). Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE Study Group. Journal of the American Medical Directors Association, 14(8), 542–559.
• Davies, M. J., et al. (2021). Semaglutide 2.4 mg once weekly for the treatment of obesity in adults without diabetes (STEP 1). New England Journal of Medicine.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., … & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine.
• Khera, R., et al. (2016). Association of weight loss with mortality risk among adults with obesity. JAMA.
• Marso, S. P., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine.
• Mehta, A., et al. (2022). Apolipoprotein B is a better marker of atherosclerotic risk than LDL-C. Journal of the American College of Cardiology.
• Packer, M., et al. (2020). Pathophysiologic mechanisms underlying HFpEF in obesity. New England Journal of Medicine.
• Powell-Wiley, T. M., et al. (2021). Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation.
• Rimm, E. B., et al. (1996). Mediterranean diet and cardiovascular risk. New England Journal of Medicine.
• Rubino, D., et al. (2021). STEP 4: Continued treatment with semaglutide vs. withdrawal. New England Journal of Medicine.
• Sattar, N., et al. (2023). Semaglutide and cardiovascular outcomes in overweight/obesity (SELECT). New England Journal of Medicine.
• Solomon, T. P. J., & Haus, J. M. (2012). Exercise and insulin sensitivity in obesity. Diabetes.
• Toth, P. P., et al. (2020). ApoB and ASCVD risk: Evidence and clinical use. Journal of the American College of Cardiology.
• Whelton, P. K., et al. (2018). 2017 ACC/AHA blood pressure guideline. Hypertension.
• Yki-Järvinen, H. (2016). NAFLD, insulin resistance, and metabolic syndrome. Diabetes.
• Cardiovascular Diabetology Editorial (2024). Insulin resistance indices and mortality associations in US adults (NHANES 2001–2018). Cardiovascular Diabetology.
• Look AHEAD Research Group. (various years). Long-term effects of lifestyle intervention on weight and cardiometabolic outcomes. Multiple publications.
• LeBlanc, E. S., Joffe, H., & Shifren, J. L. (2023). Management of menopause symptoms. JAMA.
• Lovejoy, J. C., Champagne, C. M., de Jonge, L., Xie, H., & Smith, S. R. (2008). Increased visceral fat and decreased energy expenditure during the menopausal transition. International Journal of Obesity, 32(6), 949–958.
• NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause.
• Phillips, S. M. (2015). Nutritional supplements in support of resistance exercise to counter age-related sarcopenia. Advances in Nutrition, 6(4), 452–460.
• Thurston, R. C., Chang, Y., Buysse, D. J., Hall, M. H., & Matthews, K. A. (2019). Hot flashes and weight gain in midlife women. Fertility and Sterility.
• Husain, M., et al. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine.
• Bohannon, R. W. (2019). Grip strength: An indispensable biomarker for older adults. Clinical Interventions in Aging, 14, 1681–1691.
• AASLD and FDA resources on MASLD/MASH and resmetirom (accessed 2026). Guidelines and communications, FDA resmetirom updates.
• AASM/Journal of Clinical Sleep Medicine resources on OSA screening and CPAP adherence (accessed 2026). Sleep screening and management standards.
• The Lancet (2024). Semaglutide and knee osteoarthritis pain reduction in people with obesity (STEP-9 related reports).
• Physiological Society and Nature reviews (various). Exercise physiology, AMPK, GLUT4; HPA axis and appetite hormones, [https://www.nature.com/].

Note: Readers should consult the most current guidelines and peer-reviewed sources for updates beyond these references, as the field continues to evolve rapidly.

SEO tags: obesity care, insulin resistance, cardiometabolic syndrome, semaglutide, tirzepatide, HFpEF, dyslipidemia, hypertension, MASLD, MASH, NAFLD, sleep apnea, CPAP, depression, anxiety, menopause, vasomotor symptoms, sarcopenic obesity, protein intake, anabolic resistance, integrative chiropractic, functional medicine, rehabilitation, personal injury, El Paso, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC, HOMA-IR, apoB, CAC, FIB-4, DEXA